BioCentury | Oct 25, 2014
Company News

Venture Tracks

...a professor at Massachusetts Institute of Technology and a co-founder of Epizyme Inc. (NASDAQ:EPZM) and Idun Pharmaceuticals Inc....
BioCentury | Sep 15, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Sep 15, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | May 19, 2014
Clinical News

Emricasan: Phase IIb started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Mar 10, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Dec 9, 2013
Clinical News

Emricasan: Phase I data

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Dec 9, 2013
Clinical News

Emricasan regulatory update

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Sep 16, 2013
Clinical News

Emricasan: Phase II started

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...
BioCentury | Sep 16, 2013
Clinical News

Emricasan: Phase IIb started

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...
BioCentury | Jul 26, 2013
Financial News

Conatus raises $66 million in IPO

...treat chronic liver failure in 2H14. Conatus gained emricasan through its 2010 acquisition of the Idun Pharmaceuticals Inc....
Items per page:
1 - 10 of 116
BioCentury | Oct 25, 2014
Company News

Venture Tracks

...a professor at Massachusetts Institute of Technology and a co-founder of Epizyme Inc. (NASDAQ:EPZM) and Idun Pharmaceuticals Inc....
BioCentury | Sep 15, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Sep 15, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | May 19, 2014
Clinical News

Emricasan: Phase IIb started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Mar 10, 2014
Clinical News

Emricasan: Phase II started

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Dec 9, 2013
Clinical News

Emricasan: Phase I data

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Dec 9, 2013
Clinical News

Emricasan regulatory update

...in liver transplant recipients with reestablished fibrosis. Conatus gained emricasan through its acquisition of the Idun...
BioCentury | Sep 16, 2013
Clinical News

Emricasan: Phase II started

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...
BioCentury | Sep 16, 2013
Clinical News

Emricasan: Phase IIb started

...transplant due to HCV infection this half. Conatus gained emricasan through the acquisition of the Idun...
BioCentury | Jul 26, 2013
Financial News

Conatus raises $66 million in IPO

...treat chronic liver failure in 2H14. Conatus gained emricasan through its 2010 acquisition of the Idun Pharmaceuticals Inc....
Items per page:
1 - 10 of 116